Biomerica Receives Approval in Egypt for Complete Range of Rapid Diagnostic Tests
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Source: NASDAQ.COM
Biomerica's Approval: Biomerica, Inc. received authorization from the Egyptian Drug Authority for its complete range of rapid tests related to cancers and chronic diseases.
Test Portfolio: The approved tests include at-home options such as the EZ Detect Colon Disease Test, Aware Breast Self Exam, Fortel Prostate (PSA) Screening Test, Fortel Kidney Disease Screening Test, and Fortel Ulcer (H. pylori) Screening Test.
Market Reaction: Following the announcement, Biomerica's shares increased by over 4% in pre-market trading, closing at $2.50, which was a 1.62% rise from the previous day.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like BMRA with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on BMRA
About BMRA
Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biomerica (BMRA) Reports Q2 Loss of $1.32 Million, Revenue Down 26.2%
- Widening Losses: Biomerica reported a net loss of $1.32 million in Q2, a 39.5% increase from last year's loss of $0.95 million, indicating greater pressure on the company's profitability.
- Revenue Decline: The company's revenue fell to $1.21 million, down 26.2% from $1.64 million last year, reflecting weak market demand and sales challenges that could impact future liquidity.
- Performance Comparison: The loss per share widened from $0.09 to $0.12 compared to the same period last year, suggesting that efforts to control costs and boost revenue have not yielded expected results.
- Market Outlook: With both revenue and profitability declining, Biomerica may need to reassess its market strategy to navigate the current economic environment and competitive pressures in the industry.
Continue Reading
Biomerica (BMRA) Reports Q2 Net Loss of $1.32M, Revenue Down 26.2% YoY
- Financial Performance Decline: Biomerica reported a Q2 net loss of $1.32 million, which is a 39% increase from a $0.95 million loss in the same quarter last year, indicating greater pressure on the company's profitability.
- Significant Revenue Drop: The company's revenue fell to $1.21 million, down 26.2% year-over-year, reflecting weak market demand and insufficient sales strategies, which could impact future liquidity.
- Investor Attention: As financial performance worsens, investor interest in Biomerica is likely to increase, potentially leading to heightened stock price volatility and affecting the company's ability to raise capital in the market.
- Uncertain Future Outlook: Given the current financial situation, Biomerica needs to reassess its business strategy to address market challenges and restore growth potential.
Continue Reading